DRDO Corona Vaccine 2021, At the End of December 2019 millions of people around world suffered ill from Corona -19 virus. Many people lost their loved ones, family.
Read more: What To Do After Science 12th
This Covid-19 made the world to face the financial crisis. where most of the businees ,comapnies shut down permanently.
DRDO Anti Covid Drug (2DG Medicine) Approved, Efficacy, Price, Vaccine Name, Side Effects, Availability details are discussed here. DCGI – Drug Controller General of India was testing DRDO 2-DG medicine for Corona Virus. Finally on 9th May 2021, DCGI approved the emergency use of DRDO Anti Covid Drug. The medicine is developed by the Institute of Nuclear Medicine and Allied Sciences which is formally known as INMAS. INMAS is a lab of Defence Research and Development Organisation – DRDO. INMAS worked in collaboration with Dr. Reddy’s Laboratories in Hyderabad to develop DRDO 2DG medicine.
Dr. Reddy’s Laboratory is a premier contracted laboratory of DRDO. In its 48 years of functioning, they developed 123 kinds of diagnostic test machines such as those for cancer, diabetes, heart, respiratory, eye, liver and respiratory diseases. Let us know more about them. Dr. Kumaraswamy, who was given the charge of INMAS in 2009, started his work in producing two-dimensional (2D) gel electrophoresis which is a powerful method to detect specific substances and antibodies in bio fluids like blood, urine, breast milk, and saliva. Two-dimensional gel electrophoresis involves the separation of plasmids of DNA within a substance known as an electrophoretic medium. The plasmids and the data of electrophoresis are loaded onto polyacrylamide gels and exposed to an electric field. In 2D gels, the nucleic acids are in proximity with each other. When the electric field is passed across the nuclei, specific hybridization patterns of the nucleic acids are established. After a few years, within the framework of INMAS, Dr. Kumaraswamy and his team started to develop a number of diseases and cancer which they succeeded in treating using this two-dimensional technique. The principal reason behind the success of this technology was the high correlation between the presence of 2D gels and tumor cells as detected by electron microscopic staining. This meant that a patient’s cancerous cells were strongly concentrated in gel regions where the therapy failed. Prior to conducting these trials, there was no technology which could clearly indicate the presence or lack of high-grade cancerous cells in the respective blood samples of patients. The failure of the primary echocardiography in 90% cases could be due to the poor quality of the electrophoretic medium. This led in 1982, to the invention of electron micrograph or EMG, a mobile electron microscope in which single small cancer cells or spots can be clearly identified with high-resolution. This developed into the quantum dot echocardiography (Q-EMG) technology and developed by Dr. Kumaraswamy and his team led by Dr. Prasad.
The successful treatment of a syndrome known as T-cell Lymphoblastic Leukemia (CTLL) was achieved using EMG. Electrophoretic gels were employed in diabetes drugs for testing possible new treatment regimens.
The team developed an automated method to detect different relapse patterns of cancer cells in the bone marrow using electron micrograph. The bone marrow was obtained from peripheral blood obtained from cancer patients. The blood was sent to the bone marrow biopsy facility by a specially manufactured tube, through a hand-carried catheter.
The experimental drug cocktails were made using diagnostic continuous glucose microarray technology. The drug cocktails were first searched for says Prasad in press conferences.
Price of the medicine is Rs.2000 per capsule, which will be available in the second half of 2021. The tablets themselves will be available in packs of four. They will be sold at a discount priced at Rs.1000 per pack now. Price of the medicine is quoted at Rs.4,500 for the first 50 complaints of Covid-19. After that, the price will be Rs.5,500 ($55) per month being the current prices. 15% of the first 50 packs sold will be given to Market for use by PPP VI credit card holders. In addition, the remaining 85% of the pizza will be given to the COVID-19 — countries to be announced later.
After having purchased the medicine, consumers will have to take it at home and contact their physician. DCGI said nobody should suffer in these times. Prof. Rajiv Mehrabian, Director General of IPRAD, the apex body for the IPRAD organisation in India, approved the drugs. According to Mehrabian, these are going to be the North Block of India. He said; “Considering the significant number of premature deaths in the country, the mass scale distribution of these types of vaccines would decrease the burden of a pandemic on the society and contribute also towards India’s goal of complete eradication of coronavirus from the earth.” PROBLEM TO BE SOLVED: Aspinall’s disease (an immune-mediated disease caused by the Cyprinids) makes up to 15 percent of all hospitalisations in the world.
The World Health Organization estimates that about 25 to 30 to 300 million people will be infected with the disease. Aspinall’s disease can be spread organically through aerosols from coughing or sneezing. As Pinkeye is spread by breathing in contaminated air, it’s one of the worst diseases to go viral, very hard to cure. The vaccine currently exists in 65 countries and 20 in Europe. Unfortunately, as the disease is not always within the respiratory tract, it isn’t the best option for health workers treating it. In low doses, it is effective.
The concentration achieved for isolation of the virus by the aerosol after aerosol generation is only a fraction of the blood serum concentration, so high-level of manual dexterity is required. This limits the amount of the dose that could actually reach the target sites resulting in some deaths. Since COVID-19 is now a pandemic and the two main fears are inhalation and contact, one of the only effectiveness are the aerosols themselves. The aerosols appear to be inhaled for 3 to 5 minutes and larger particles are emitted. Once in the nasal cavity, in less than three minutes, they remain in the respiratory tract living up to several hours, thus many hours after clearing the inhaled aerosol.
In doing research to develop anti-viral drugs for a variety of diseases, INMAS found the opioid receptor antagonist barbiturates and levetiracetam as promising candidates for developing an anti-cancer drug called 2DG/CRV1 Vaccine. The contributions of INMAS were also greatly assisted by MIT Agri-Tech Synergistic Collaborative Research and Development Organisation (R&D Organisation) under the MITIS and the Platform Application. So far, a total of 8 collaboration projects have come up. Participating in multiple drug projects, technical workshops as well as synthesising of new compounds leading to new drug candidates. Now, DRDO has announced that it had successfully developed anti-viral drug,2DG/CRV1 Vaccine. Thousands of Indians will get this vaccine in a few days. A working group under the co-operation of INMAS had been developing the drug therapy as early as in 2017. The INMS had also kick-started the development project in the last year of the last decade under the title ‘Generation of a novel antiviral drug using G-CSF’ by Sathyabama University.
As per the reports by Dr. Reddy, from the lab of INMS, the outer membrane liposome drug was shown to be effective against Las Vegas Covid-19 in cell culture. In 2021, a small percentage of the doses will be distributed from a national mega cell, planned to be set up from the National Institute of Pharmaceutical Education and Research (NIPPER) near Chennai. “Once the vaccine arrives here, we should be able to start our war against the coronavirus by the middle of the year.” After working on the development of 2DG/CRV1 Vaccine and exploring various potential solutions facing global public health disasters, the DRDO has come up with the initial design of its Catalyst Catalyst Cell System. The Catalyst Cell System is a Matrix centre-based modelling and simulation architecture aggregated into one instrument.
It generates the design constraints, collects material knowledge to anticipate material requirements in the material preparation and streamline the production process. The Catalyst Cell System was initially developed in-house. The therapist in the Catalyst Cell System is a futuristic man-machine interface, addressing both manual and artificial intelligence.
In a first phase, the Catalyst Cell System will be introduced in a ten node cell system, testing the efficacy of a wound dressing solution. The system was developed using clean room techniques and 0.3 micron copper nanowire nan rods with a diameter of 20 nanometers for guiding drug particles released from capsules.
The nano water would disperse the drug particles inside the cell with ultra-low concentrations. The system will be expanded to form a total of 100 cells set up in different environments. Over 100 experiments would be carried out in collaboration between different DRDO industrial units by end-2021.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]